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1.1 INTRODUCTION 
 The cystic fibrosis transmembrane conductance regulator (CFTR)1 is an ATP-binding 
cassette (ABC) transporter.2  ABC transporters are found in all organisms, where they perform 
diverse physiological roles.  The vast majority of ABC transporters pump assorted substrates 
across cell membranes either into (importers) or out of (exporters) cells.2  Some ABC 
transporters (e.g. the sulphonylurea receptor; SUR1 (ABCC8; pancreas) and SUR2 (ABCC9; 
heart and muscle)) regulate associated ion channels.3,4  But, only CFTR (ABCC7) forms an ion 
channel.5,6 
 
 CFTR is principally expressed in the apical membrane of epithelia throughout the body 
lining ducts and tubes.7  It controls the quantity and composition of epithelial secretions by (i) 
forming a small-conductance (6-10 pS) anion-selective channel with complex regulation8,9 and 
(ii) regulating the function of other ion channels and transporters.10,11  Thus, CFTR plays a 
pivotal role in epithelial physiology that influences development, growth, innate immunity and 
fecundity.  The importance of CFTR is dramatically highlighted by three common diseases: 
cystic fibrosis (CF), secretory diarrhoea and autosomal dominant polycystic kidney disease 
(ADPKD).  CF is caused by loss-of-function mutations in CFTR,7 whereas secretory diarrhoea 
and ADPKD are associated with unphysiological CFTR activity.12,13  However, these are not the 
only diseases linked to CFTR.  Some forms of male infertility, pancreatitis and bronchiectasis are 
termed CFTR-related disorders because they are caused by mutations that preserve partial CFTR 
function,14 while some reproductive disorders involve unphysiological CFTR activity.15 
 
Here, we review selectively the therapeutic potential of small-molecule CFTR 
modulators in the treatment of CF, secretory diarrhoea and ADPKD.  We discuss how CFTR’s 
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physiological role and malfunction in disease have informed drug development.  We explore the 
structure and function of CFTR to understand the mechanism of action of small-molecule CFTR 
modulators.  Finally, we consider some of the challenges to be overcome before small-molecule 
CFTR modulators realise their promise as therapeutics. 
 
1.2 THE PATHOPHYSIOLOGY OF CFTR 
1.2.1 The physiology of CFTR 
 CFTR plays a crucial role in regulating the quantity and composition of epithelial 
secretions throughout the body.  However, examination of the physiology of individual epithelia 
reveals tissue-specific differences in CFTR function.  A variety of factors contribute to this 
diversity including tissue architecture, the distribution of proteins that interact with CFTR to 
modulate its expression and function and the role of CFTR as both an anion channel and 
transport regulator. 
 
Ducts and tubes in the pancreas, intestine, hepatobiliary system and reproductive tissues 
transport a variety of protein-rich cargoes.  For this purpose, these ducts and tubes are lined by 
epithelia, which secrete fluid and electrolytes to lubricate their surfaces (Fig. 1).7,16  The process 
involves the active transcellular movement of Cl- and the passive paracellular movement of Na+ 
and water.  A series of ion channels and transporters in the basolateral membrane accumulate 
actively Cl- inside epithelial cells.  However, CFTR plays the pivotal role by providing an apical 
membrane pathway for Cl- to exit passively from cells down a favourable electrochemical 
gradient and a key point at which to regulate transepithelial fluid and electrolyte movements 
(Fig. 1).  By contrast, in sweat duct epithelia, the coordinated activity of CFTR and the epithelial 
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Na+ channel (ENaC) reabsorb salt across a water-impermeable epithelium to generate a 
hypotonic fluid in the duct lumen that emerges onto skin as sweat (Fig. 1).  Interestingly, CFTR 
is located in both the apical and basolateral membranes of sweat duct epithelia where it provides 
pathways for passive Cl- transport across the epithelium following active Na+ transport.7,17 
 
 Like sweat duct epithelia, airway epithelia possess both CFTR and ENaC channels in 
their apical membrane (Fig. 1).  They also possess a similar repertoire of basolateral membrane 
ion channels and transporters to those found in secretory epithelia.  Thus, airway epithelia either 
absorb or secrete fluid and electrolytes depending on the prevailing electrochemical gradient and 
neurohumoral signals.7,16,18  The coordinated activity of CFTR and ENaC in airway epithelia 
generates the thin layer of airway surface liquid (ASL) above which lies a mucus gel that traps 
debris in inhaled air (Fig. 1).  Beating cilia protruding from the apical membrane of airway 
epithelial cells propel mucus up the airways to remove debris from the lungs (termed mucociliary 
clearance).  CFTR is also expressed in serous cells of submucosal glands in the proximal 
airways.  CFTR-driven fluid and electrolyte secretion by these cells flushes mucins and 
antimicrobial factors from submucosal glands onto the surface epithelium where they play 
important roles in mucociliary clearance and host defence.19 
 
 In the kidney, CFTR is differentially expressed along the length of the nephron,20 where 
it serves several functions.  First, CFTR acts as a regulated anion channel to transport Cl- across 
the apical membrane of epithelial cells in different nephron segments.21  Second, some data 
suggest that CFTR co-assembles with the renal outer medullar potassium (ROMK) channel 
(Kir1.1) to form the ATP-sensitive K+ channel that recycles K+ across the apical membrane of 
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epithelial cells in the thick ascending limb of the loop of Henle during salt reabsorption.22  Third, 
CFTR stabilises cubulin expression during receptor-mediated endocytosis in the proximal 
tubule.23  Thus, CFTR plays wide-ranging roles in epithelial physiology.  Loss of CFTR function 
or unphysiological CFTR activity has profound consequences for epithelial ion transport and 
human health.  Below, we consider CF, secretory diarrhoea and ADPKD. 
 
1.2.2 Cystic fibrosis 
 The genetic disease CF is an important medical problem, accounting for most cases of 
severe chronic obstructive lung disease and exocrine pancreatic dysfunction in Caucasian 
children and young adults.7,24  Current therapies for CF are directed against disease symptoms, 
not its root cause CFTR malfunction.  They include physiotherapy, mucolytic drugs and 
antibiotics to treat lung disease, and pancreatic enzyme replacement therapy and supplemental 
nutrition to overcome gastrointestinal dysfunction.7,24  Together with specialist patient care in CF 
centres, improvements in symptomatic therapy have increased average life expectancy to around 
40 years in North America and some European countries.24 
 
 The wide-ranging manifestations of CF, including chronic lung disease, exocrine 
pancreatic insufficiency, meconium ileus, male infertility and salty sweat are caused by defective 
CFTR-mediated fluid and electrolyte movements across epithelia.7  CFTR malfunction in 
secretory epithelia prevents their lubrication leading to the stasis of protein-rich cargoes, the 
obstruction and ultimately destruction of ducts and tubes in organs such as the pancreas, 
intestine, hepatobiliary system and reproductive tissues.  By contrast, loss of CFTR function in 
CF sweat ducts leads to salty sweat, a hallmark used clinically to diagnose the disease.17 
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 The major cause of morbidity and mortality in CF is progressive chronic lung disease.  
CF lung disease is caused by defective epithelial ion transport, which impairs mucociliary 
clearance leading to mucus accumulation, airway obstruction and persistent bacterial 
infections.7,18,25  In general, there are two mechanisms by which CF mutations cause harm.  First, 
the mutant protein is not delivered to the apical membrane of epithelial cells.  Second, the mutant 
protein is present at the apical membrane, but its function is altered.  Both mechanisms are 
exemplified by the most common CF mutation, F508del, the deletion of a phenylalanine residue 
at position 508 of the CFTR protein sequence, which is located in the first nucleotide-binding 
domain (NBD1).  About 70% of CF patients carry two copies of the F508del mutation and 90% 
at least one.  The prevalence of the F508del mutation argues strongly that it is the primary target 
for therapy development. 
 
 The molecular basis for the F508del defect is protein misfolding, which causes retention 
of the mutant protein in the endoplasmic reticulum and its subsequent degradation by the 
proteasome.26-28  The vast majority of F508del-CFTR therefore fails to reach its correct cellular 
location.  Worse, the little that reaches the apical membrane is unstable, residing there for < 4 h 
compared with > 24 h for wild-type CFTR.29  The F508del-CFTR mutation also disrupts 
severely CFTR channel gating (Fig. 2).30  For wild-type CFTR, channel openings occur 
frequently and are separated by short periods of channel closure (Fig. 2).  By contrast, F508del-
CFTR channel openings occur infrequently and are separated by prolonged periods of channel 
closure (Fig. 2). 
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 In airway epithelia, loss of CFTR-driven transepithelial fluid and electrolyte transport has 
three main consequences.  First, defective HCO3- secretion prevents secreted mucins expanding 
to form mucus-gel networks; instead they remain aggregated and difficult to transport.31  Second, 
CFTR malfunction in submucosal glands disrupts the secretion of fluid, mucins and anti-
microbial factors onto the surface epithelium.19  Third, CFTR malfunction in the surface 
epithelium depletes ASL.18  This latter defect highlights the dual roles of CFTR as a Cl- channel 
and transport regulator.  Loss of CFTR Cl- channel function prevents fluid and electrolyte 
secretion onto the surface epithelium, whereas dysregulation of ENaC by CFTR leads to 
excessive absorption of Na+ and fluid, dehydrating ASL.18  Loss of ASL impairs mucociliary 
clearance because cilia are unable to beat effectively on dehydrated airway surfaces.  Mucus 
accumulation causes airway obstruction.  Moreover, defective mucus transport results in 
persistent infection of CF airways by microbial pathogens (e.g. Pseudomonas aeruginosa).7  
Bacterial infections trigger inflammatory responses in CF airways that are excessive in 
magnitude and protracted in duration.  Together, infection and inflammation play a central role 
in the destruction of lung tissue in CF, leading to bronchiectasis, emphysema and end-stage lung 
disease. 
 
1.2.3 Secretory diarrhoea 
 The commonest cause of secretory diarrhoea is infection of the small intestine by 
enterotoxin-producing bacteria most notably Vibrio cholerae and Escherichia coli.12  These 
bacteria do not damage the intestinal epithelium.  Instead, they cause disease by modifying 
profoundly transepithelial ion transport in the small intestine.  For example, it is not unknown for 
cholera patients to expel more stools than their own body weight.32  Contamination of water 
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supplies with enterotoxin-producing bacteria is a major global health problem, causing the death 
of several million lives annually, mostly young children in underdeveloped countries.33  
However, these organisms, especially Escherichia coli, also cause disease in developed 
countries, particularly among vulnerable young and elderly populations. 
 
Cholera toxin, the major toxin secreted by Vibrio cholerae and Escherichia coli heat 
labile toxin have identical cellular mechanisms of action, targeting adenylyl cyclase in intestinal 
epithelial cells to activate the cAMP signaling cascade leading to the phosphorylation of target 
proteins by protein kinase A (PKA).12  By contrast, Escherichia coli heat stable toxin activates 
guanylate cyclase and hence, cGMP-dependent protein kinase (PKG) in intestinal epithelial 
cells.34  Activation of the cAMP signaling cascade in the small intestine stimulates CFTR-
mediated transepithelial Cl- secretion by crypt epithelial cells.12  It also inhibits electroneutral salt 
reabsorption by villus epithelial cells in the small intestine and stimulates K+ secretion by crypt 
epithelial cells in the colon.12  Like PKA, PKG phosphorylates CFTR leading to the activation of 
CFTR-mediated transepithelial Cl- secretion by crypt epithelial cells in the small intestine.35  
Because Na+-coupled glucose absorption by villus epithelial cells is unaffected by PKA and 
PKG, oral rehydration therapy (ORT) with isosmolar sodium glucose solutions is the treatment 
of choice for secretory diarrhoea in all countries.36  Although ORT effectively rehydrates 
afflicted patients, it does not lessen the diarrhoea.12  For this reason, pharmacological 
interventions to prevent diarrhoea (e.g. small-molecule CFTR inhibitors) would be a welcome 
adjuvant to ORT. 
 
1.2.4 Autosomal dominant polycystic kidney disease 
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 ADPKD is the most common single gene disorder to affect kidney function, with an 
incidence of approximately 1 in 1000 live births in all ethnic groups.37  The disease is caused by 
mutations in the polycystin proteins (polycystin-1 and polycystin-2) that initiate a cascade of 
events, which result in the formation of multiple epithelial cysts containing a fluid-filled cavity 
surrounded by a single layer of immature renal epithelial cells.37-39  The development and growth 
of cysts in ADPKD is accelerated by activation of the cAMP signal transduction cascade, which 
stimulates the proliferation of ADPKD epithelial cells and fluid accumulation within the cyst 
lumen powered by CFTR-mediated transepithelial Cl- secretion.13,40  The insidious formation and 
growth of multiple ADPKD cysts progressively destroys kidney function leading to severe renal 
failure.37,38  At present, there are no cures for ADPKD, which accounts for approximately 7-10% 
of patients requiring kidney transplantation and dialysis.38  Among the many approaches now 
under consideration to develop rational new therapies for ADPKD,37 one strategy is to prevent 
fluid accumulation within ADPKD cysts using small-molecule CFTR inhibitors. 
 
1.3 CFTR STRUCTURE AND FUNCTION 
 CFTR has a modular design composed of two membrane-spanning domains (MSDs), two 
nucleotide-binding domains (NBDs) and a unique regulatory domain (RD).8,9  The MSDs are 
composed of six transmembrane segments linked by short extracellular, but long intracellular 
loops.  The NBDs possess conserved ATP-binding motifs (ABC signature (LSGGQ) sequence 
and Walker motifs).  The RD is distinguished by multiple consensus phosphorylation sites and 
many charged residues. 
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 Initial efforts to investigate CFTR structure and function utilised functional studies of 
CFTR constructs bearing site-directed mutations.  This work demonstrated that CFTR is a small 
conductance anion-selective channel with complex regulation.  The MSDs form an anion-
selective pore, but instead of multiple transmembrane segments governing conduction and 
permeation, the sixth transmembrane segment (M6) plays a dominant role.8,41  Phosphorylation 
of the RD by PKA at multiple consensus sites is a prerequisite for CFTR activity.8,42  ATP 
binding and hydrolysis at the NBDs control the opening and closing of the CFTR pore.8,42  But, 
detailed mechanistic insight has for a long time been lacking. 
 
 The elucidation of crystal structures of isolated NBDs (e.g. CFTR NBD1)43 and intact 
ABC transporters, especially Sav1866, the multidrug transporter of Staphylococcus aureus,44 
revolutionised understanding of CFTR structure and function.  They revealed that the NBDs 
function as a head-to-tail dimer with two ATP-binding sites located at the dimer interface (Fig. 
3).  One ATP-binding site is formed by the Walker A and B motifs of NBD1 and the LSGGQ 
motif of NBD2 (termed site 1), while the other is formed by the Walker A and B motifs of NBD2 
and the LSGGQ motif of NBD1 (termed site 2) (Fig. 3).43  Structural studies also illuminated the 
impact of CF mutations on CFTR function.  For example, F508, the site of the commonest CF 
mutation, is located remote from the NBD dimer interface on the surface of NBD1 in a prime 
position to interact with the MSDs (Fig. 3).43  By contrast, other CF mutations (e.g. G551D and 
G1349D) affect critical residues in the two ATP-binding sites (Fig. 3), providing explanations 
for the deleterious effects of these mutations on CFTR channel gating.45,46 
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 Vergani et al.47 integrated biochemical (e.g. Aleksandrov et al.48) and functional (e.g. 
Zeltwanger et al.49) data with the results of structural studies of ABC transporters to propose the 
ATP-driven NBD dimerisation model of CFTR channel gating.  In this model, CFTR channel 
gating is controlled by ATP binding and hydrolysis at site 2 driving cycles of NBD dimer 
assembly and disassembly.  In support of this model, R555 (NBD1) and T1246 (NBD2), two 
residues on either side of ATP-binding site 2 are energetically coupled in open, but not closed 
channels, arguing that the NBDs change their conformation during channel gating.50  However, 
subsequent studies revealed that ATP hydrolysis at ATP-binding site 2 leads to partial, not full 
separation of the NBD dimer.51,52  Thus, during the gating cycle, ATP-binding site 1 remains 
tightly closed around a bound ATP molecule, whereas ATP-binding site 2 undergoes 
conformational changes, closing following binding of an ATP molecule to form the NBD dimer, 
but opening again after ATP cleavage to release the hydrolytic products. 
 
 Dynamic reorganization of the NBDs in turn power conformational changes of the MSDs 
that gate the CFTR pore to control anion flow.  Studies of CF mutants (e.g. Cotton et al.53) had 
suggested that the intracellular loops (ICLs) which connect transmembrane segments within the 
MSDs play a crucial role in coupling the NBDs to the CFTR pore.  However, confirmation 
required the development of structural models of CFTR by Serohijos et al.54 and Mornon et al..55  
In these structural models, each ICL consisted of two long α-helical extensions of 
transmembrane segments with an intervening short α-helix at its most cytoplasmic location 
orientated parallel to the plane of the membrane.  Because this short α-helix interacted with the 
NBDs, it was termed the coupling helix.54,55  Several important conclusions about NBD-MSD 
communication are suggested by the structural models of Serohijos et al.54 and Mornon et al..55  
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First, the ICLs communicate with both the same and the opposite NBD (e.g. ICL1 (MSD1) with 
NBD1 and ICL2 (MSD1) with NBD2).  Second, the coupling helices of ICL1 and ICL3 interact 
directly with ATP-binding sites 1 and 2, respectively.  Third, the coupling helix of ICL4 interacts 
with F508.  Thus, the F508del mutation affects a critical interface in the CFTR Cl- channel. 
 
 Electron crystallography of two-dimensional CFTR crystals suggested that the CFTR 
pore resembles an asymmetric hour-glass, with a deep wide intracellular vestibule and a shallow 
extracellular vestibule separated by a constriction.56  This image of the CFTR pore demonstrates 
striking agreement with predictions from functional studies.8,41  Building on these studies, 
Norimatsu et al.57 used cysteine scanning mutagenesis to test the predicted orientation of amino 
acid side-chains in M3, M6, M9 and M12 from a Sav1866-based molecular model of the CFTR 
pore.  The authors’ data suggest that the constriction in the CFTR pore is located towards the 
extracellular end of the channel with the boundary between the outer vestibule and the 
constriction located near T338 (M6) and I1131 (M12) and that between the constriction and the 
inner vestibule located near S341 (M6) and T1134 (M12).  Functional evidence argue that the 
pore constriction determines the anion selectivity of the CFTR,58 exhibiting characteristics of a 
lyotropic series (i.e. anions with the lowest free energy of hydration enter first and bind 
strongest).59  In support of the degraded ABC transporter model of CFTR function,60 the 
constriction is also a plausible location of the gate, which controls anion flow through the CFTR 
pore.61  However, other studies argue that the gate might occupy a more cytoplasmic location 
within the CFTR pore.62  Identifying the location of this gate is crucial to understand the CFTR 
gating pathway, the sequence of conformation changes initiated by ATP binding to the NBDs 
that lead to Cl- flow through the CFTR pore.  In turn, this knowledge as well as information 
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about the architecture of the CFTR pore is vital to understand the mechanism of action of small-
molecule CFTR modulators. 
 
1.4 RESTORATION OF CFTR FUNCTION 
 To target the root cause of CF, future therapies should (i) overcome the F508del-CFTR 
processing defect and traffic the mutant protein to the apical membrane;26 (ii) extend the 
residence time of F508del-CFTR at the apical membrane29 and attenuate channel “rundown” 
(e.g. Schultz et al.63) and (iii) rescue the defective channel gating of F508del-CFTR.30  Thus, 
small-molecules with two, possibly three types of activity are required to suppress the deficits in 
F508del-CFTR expression and function. 
 
 Some CFTR modulators (e.g. genistein)64 were identified using conventional assays of 
CFTR function.  However, by far the most successful strategy is high-throughput screening 
(HTS).65  HTS exploits a reliable, sensitive, cost-effective assay to screen libraries of chemically 
diverse small-molecules to identify lead compounds for medicinal chemistry optimisation.  For 
further information about the use of HTS to discover small-molecule CFTR modulators, see 
Verkman & Galietta.65  Below, we discuss selectively, small-molecules that rescue the 
expression and function of F508del-CFTR. 
 
1.4.1 CFTR correctors 
 Small-molecules that overcome the processing defect of F508del-CFTR to rescue its cell 
surface expression are termed CFTR correctors.65,66  CFTR correctors might interact directly 
with CFTR, by acting as substrate mimics or active site inhibitors.  Alternatively, they might 
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target one or more of the many CFTR interacting proteins that orchestrate and control CFTR 
processing, its delivery to, and expression at the apical membrane.  This latter group of CFTR 
correctors is termed proteostasis regulators because they aim to treat CF by manipulating the 
concentration, conformation, quaternary structure and/or location of CFTR.67 
 
 The Cystic Fibrosis Foundation (Bethesda, USA), a nonprofit, donor-supported 
organization, developed a new model for supporting drug development (termed Venture 
Philanthropy) when it funded Aurora Biosciences then Vertex Pharmaceuticals to develop small-
molecule therapies that target directly CF mutants.  The first CFTR corrector identified by 
Vertex Pharmaceuticals was the quinazoline VRT-325, which restored CFTR function to CF 
bronchial epithelia expressing F508del-CFTR (F508del-CFBE) to ~10% that of human bronchial 
epithelia expressing wild-type CFTR (HBE),68 an amount similar to that achieved by the 
bisaminomethylbithiazole CFTR corrector corr-4a.69  Subsequently, Vertex Pharmaceuticals 
developed VX-809 (Fig. 4), a potent, selective and orally bioavailable CFTR corrector that 
partially restores CFTR expression and function to F508del-CFBE.70  Treatment of cells 
expressing recombinant F508del-CFTR with VX-809 (3 μM) for 24 h abrogated the protease-
sensitivity of mutant protein and accelerated its conversion from the immature, core-glycosylated 
form (band B) to the mature, fully-glycosylated form (band C).70  These data suggest that VX-
809 promotes the correct folding and intracellular transport of a fraction of F508del-CFTR 
protein.  Strikingly, following treatment with VX-809 (3 μM for 24 - 48 h), F508del-CFTR Cl- 
channels exhibited the same open probability (Po) as wild-type CFTR, arguing that VX-809 
normalises the channel function of F508del-CFTR.70  Finally, when compared with other CFTR 
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correctors VX-809 demonstrated improved selectivity and greater efficacy, achieving 14% HBE 
function restored to F508del-CFBE.70 
 
 Based on the success of preclinical studies, VX-809 was tested in 89 adult CF patients 
homozygous for F508del-CFTR in a 28-day randomised, double-blind placebo-controlled (phase 
IIa) clinical trial.71  Although VX-809 was well tolerated by CF patients and caused a modest 
reduction in sweat Cl- concentration , it was without effect on patient-reported outcomes, lung 
function (measured by forced expiratory volume in one second, FEV1) and nasal potential 
difference (NPD; a measure of CFTR function in the nasal epithelium).71 
 
 A potential explanation for the lack of clinical efficacy of VX-809 is provided by two 
recent studies.72,73  Mendoza et al.72 identified an apparent efficacy ceiling among CFTR 
correctors that likely interact directly with F508del-CFTR: none had potency < 1 μM nor 
efficacy > 15% wild-type CFTR function.  To elucidate the mechanistic basis of this efficacy 
ceiling, the authors identified amino acid positions statistically-coupled to position 508 in ABC 
transporter sequences and evaluated the impact of mutations at these positions on NBD1 folding 
and CFTR protein maturation.72  Consistent with previous results (e.g. Serohijos et al.54 and 
Thibodeau et al.74), F508del altered both NBD1 folding and the interaction of NBD1 with ICL4.  
Mutations that corrected either defect alone restored partially F508del-CFTR expression and 
function.  Only combinations of mutations that rescued NBD1 folding and stabilised the 
interaction of NBD1 with ICL4 restored F508del-CFTR expression and function to wild-type 
levels.72  Identical conclusions were obtained by Rabeh et al.73 investigating the thermodynamics 
of NBD1 folding and the stability of the NBD1:ICL4 domain interface.  Taken together, the 
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results of these studies provide a framework to identify efficacious CFTR correctors that restore 
wild-type expression and function to F508del-CFTR. 
 
1.4.2 CFTR potentiators 
 Small-molecules that repair the F508del-CFTR gating defect are termed CFTR 
potentiators (not openers or activators because they do not open silent CFTR Cl- channels).65  
They interact directly with CFTR to enhance channel gating following PKA-dependent 
phosphorylation.  Some CFTR potentiators increase the frequency of channel opening (e.g. 
dichlorofluorescein) (Z Cai and DN Sheppard, unpublished observation), other CFTR 
potentiators prolong the duration of channel openings (e.g. phloxine B)75 and yet others increase 
both the frequency and duration of channel openings (e.g. UCCF-853)76 (Y Wang, Z Cai and DN 
Sheppard, unpublished observation) (Fig. 5). 
 
 The CFTR potentiator that has received greatest attention is the isoflavone genistein.64,77  
In the presence of a maximally effective concentration of the cAMP agonist forskolin (10 μM), 
genistein (50 μM) robustly enhanced F508del-CFTR activity following its delivery to the cell 
surface by low-temperature incubation (e.g. Hwang et al.78).  Genistein augments strongly 
F508del-CFTR channel activity by accelerating the rate and prolonging the duration of channel 
openings.77  Using the ATP-driven NBD dimerisation model of CFTR channel gating,47,50 Ai et 
al.79 speculated that genistein might bind at the NBD dimer interface and promote channel 
opening by lowering the free energy of the transition state.  The authors also suggested that 
genistein might slow the rate of channel closure by stabilising the NBD dimer in its ATP bound 
configuration.79  Consistent with these ideas, Moran et al.80 used virtual ligand docking with a 
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molecular model of the NBD dimer to suggest that genistein binds at the dimer interface (Fig. 6).  
The genistein-binding site is distinct from the two ATP-binding sites of CFTR.81,82  It is 
composed of sequences from both NBD1 (Walker A, Walker B and LSGGQ) and NBD2 
(LSGGQ), with those from NBD1 forming a cavity in which genistein docks.80  Because of its 
efficacy in vitro, Illek et al.83 tested genistein on CF patients bearing the G551D mutation, a 
relatively common CFTR mutation that is without effect on protein processing, but severely 
disrupts channel gating.46  Of note, application of genistein (50 μM) to the nasal epithelium of 
CF patients with the G551D mutation restored 15% of wild-type CFTR function (measured by 
NPD).83  However, genistein’s lack of potency and selectivity precludes its application in the 
clinic. 
 
 In 2012, ivacaftor (KalydecoTM; VX-770) (Fig. 4), a potent, selective and orally 
bioavailable CFTR potentiator developed by Vertex Pharmaceuticals, became the first small-
molecule targeting CFTR to be approved for patient use 
(www.cff.org/aboutCFFoundation/NewsEvents/1-31-FDA-Approves-Kalydeco.cfm).  It was 
developed from a chemical scaffold identified as a CFTR potentiator in the second round of HTS 
conducted by Vertex Pharmaceuticals to identify small-molecule CFTR modulators.68,84  By 
increasing the frequency and duration of channel openings, ivacaftor (1 μM) restored F508del-
CFTR channel activity to wild-type levels (measured by Po).  Treatment of F508del-CFBE with 
ivacaftor (10 μM) increased CFTR-mediated transepithelial ion transport (measured by short-
circuit current (Isc)) to about half those of HBE.84  Consistent with these data, ivacaftor (10 μM) 
increased ASL volume and ciliary beat frequency of F508del-CFBE to about half those of 
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HBE.84  These data suggest that ivacaftor restores partially CFTR function and rescues 
transepithelial ion transport by F508del-CFBE. 
 
 In its initial (phase II) clinical trial, ivacaftor was tested in 39 adult CF patients carrying 
the G551D-CFTR mutation.85  The patients took ivacaftor orally in 14- or 28-day blinded, 
randomised, placebo-controlled trials.  Ivacaftor was well tolerated by CF patients.85  More 
importantly, however, in CF patients receiving ivacaftor (150 mg twice daily) sweat Cl- 
concentration decreased by ~40 mmol/l to approach the normal range (< 60 mmol/l).85  At this 
dose, lung function (measured by FEV1) increased by 9%.85  A similar magnitude increase in 
lung function (measured by FEV1) was observed in the phase III clinical trial of ivacaftor, which 
involved 161 adult CF patients with the G551D-CFTR mutation.86  For three reasons, the results 
of this clinical trial were highly significant for CF patient care.  First, lung function increased 
rapidly within 2 weeks of commencing therapy and was sustained through the 48 weeks of the 
trial.86  Second, in comparison with placebo-treated patients, ivacaftor-treated patients were 55% 
less likely to experience a pulmonary exacerbation over the 48 week period, suggesting that 
ivacaftor improved lung defence against bacterial infections.86  Third, ivacaftor-treated patients 
gained significant weight (~2.7 kg) over the trial period, suggesting that ivacaftor improves 
intestinal function resulting in better absorption of nutrients.86  When ivacaftor was tested in CF 
children aged 6 – 11 years with at least one copy of the G551D mutation, very similar results 
were obtained.  Lung function improved, weight was gained and sweat Cl- concentration fell.87  
Based on the results of these trials, the FDA and EMEA approved ivacaftor for use in CF 
patients aged 6 years and older with one copy of the G551D mutation 
(www.cff.org/aboutCFFoundation/NewsEvents/1-31-FDA-Approves-Kalydeco.cfm). 
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 Finally, recent work suggests that ivacaftor might potentiate CFTR channel gating by a 
mechanism distinct from that of CFTR potentiators, which enhance ATP-dependent channel 
gating.79  Using purified, reconstituted recombinant CFTR protein, Eckford et al.88 demonstrated 
that ivacaftor opens CFTR channels following PKA-dependent phosphorylation, in the absence 
of ATP.  These and other data,88 suggest that ivacaftor enhances ATP-independent CFTR 
channel gating,89 such as that exhibited by the G551D-CFTR mutant.46  They further suggest that 
CFTR channel gating can be potentiated by multiple mechanisms.  However, the observation that 
ivacaftor potentiates multiple CF mutants,90 including some that do not disrupt CFTR channel 
gating,91 argues that it and related small-molecules will have widespread utility in the future 
treatment of CF patients. 
 
1.4.3 CFTR corrector-potentiators 
 Because F508del-CFTR disrupts both the expression and function of CFTR,26,30 the ideal 
small-molecule therapy for CF patients bearing this mutation would combine the properties of 
CFTR correctors with those of CFTR potentiators.  Consistent with this idea, Van Goor et al.68 
demonstrated that the effects of the CFTR potentiator VRT-532 on F508del-CFBE were 
synergistic with those of the CFTR corrector VRT-325.  Together VRT-325 and VRT-532 
generated levels of CFTR-mediated transepithelial ion transport in F508del-CFBE > 20% those 
in HBE.68  Similar results were observed using the CFTR corrector VX-809 and the CFTR 
potentiator ivacaftor.70  Moreover, in clinical trials both small-molecules together restored 
significant levels of lung function to some CF patients homozygous for F508del-CFTR 
(http://investors.vrtx.com/releasedetail.cfm?ReleaseID=677520), whereas by themselves neither 
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VX-809 nor ivacaftor improved the lung function of these CF patients.71,92  These data argue that 
dual-acting small-molecules, possessing corrector and potentiator activity (so called CFTR 
corrector-potentiators) have significant therapeutic potential.  But, could such molecules be 
discovered or designed? 
 
 The first two CFTR corrector-potentiators identified were discovered serendipitously.  
First, Wang et al.93 demonstrated that the CFTR potentiator VRT-532, by itself, rescues the 
misprocessing of F508del-CFTR.  Building on these data, Wellhauser et al.94 showed that VRT-
532 reduces the ATPase activity of F508del-CFTR and abrogates its protease susceptibility.  The 
authors’ data suggest that VRT-532 binds directly to F508del-CFTR to induce a change in 
conformation that improves its stability.94  They also suggest that VRT-532 enhances channel 
gating by slowing ATP hydrolysis at ATP-binding site 2.94  Second, Pedemonte et al.95 
discovered that the aminoarylthiazole corr-2b, one of the first CFTR correctors identified by 
HTS,69 exhibits dual activity as both a CFTR corrector and a CFTR potentiator.  When compared 
with small-molecules that act as CFTR correctors alone, (e.g. the bisaminomethylbithiazole corr-
4a), corr-2b generated double the amount of forskolin-stimulated CFTR Cl- current (IFSK) relative 
to the total CFTR Cl- current measured in the presence of forskolin and the CFTR potentiator 
genistein (ITOT) (corr-4a: IFSK/ITOT ~40%; corr-2b: IFSK/ITOT ~80%).95  Interestingly, 
aminoarylthiazoles are atypical CFTR potentiators; they do not act acutely, but instead require 
protein synthesis to exert their effects.95 
 
 In search of dual-acting small-molecules to rescue F508del-CFTR, Verkman and 
colleagues screened ~110,000 drug-like chemicals with their HTS assay.96  From this screen, 
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Phuan et al.96 identified cyanoquinolines, a chemical scaffold with independent CFTR corrector 
and potentiator activity.  One cyanoquinoline, CoPo-22 trafficked F508del-CFTR to the cell 
surface with comparable potency to corr-4a and potentiated F508del-CFTR channel activity with 
potency similar to genistein.96  Structure-activity relationship studies revealed that the corrector 
and potentiator activities of cyanoquinolines could be dissociated from each other.96  Molecular 
modeling suggested that cyanoquinolines require both a flexible diamine tether and a short 
bridge between the cyanoquinoline and arylamide moieties for optimal F508del-CFTR corrector 
and potentiator activities.97  Phuan et al.96 speculated that separation of corrector and potentiator 
activities might be achieved by distinct binding sites on F508del-CFTR and/or CFTR-interacting 
proteins.  By contrast, Knapp et al.97 posited the imaginative idea of a single binding site that 
alters its conformation during the processing of F508del-CFTR and its delivery to the cell 
surface.  Finally, Kalid et al.98 adopted in silico structure-based screening to search for CFTR 
correctors, potentiators and dual-acting small molecules.  Based on analyses of homology 
modeling, three binding sites for small-molecules were identified on F508del-CFTR: (i) the 
NBD1:NBD2 interface, (ii) the NBD1:ICL4 cavity formed by deletion of F508 and (iii) the 
interface of NBD1 and NBD2 with ICL1, 2 and 4 (Fig. 6).98  From 100,000 chemicals screened 
in silico and 496 selected for functional testing, two CFTR corrector-potentiators were identified.  
EPX-108380 docked at the NBD1:NBD2 interface, while EPX-107979 docked at the 
NBD1:NBD2:ICL1, 2 and 4 interface.98  This study demonstrates convincingly the utility of in 
silico structure-based screening to search for CFTR modulators. 
 
1.4.4 Towards the therapeutic application of CFTR correctors and potentiators 
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 The application of HTS to CFTR drug discovery has led to the identification of abundant 
small-molecules that rescue the expression and function of CF mutants.65  The pressing challenge 
now is to transform discoveries in the laboratory into effective therapies for CF patients.  The 
pioneering efforts of Vertex Pharmaceuticals especially the success of ivacaftor demonstrate 
convincingly the value of targeting directly CFTR with small-molecules.  However, they urge 
further prompt progress to develop CFTR correctors and potentiators for CF patients with the 
F508del mutation, the largest group of CF patients. 
 
 The amount of function that must be restored to individual CF mutants to achieve 
therapeutic benefit is currently unknown.  Some attempts have been made to address this 
fundamental question by analysing published data on the relationship between the genotype of 
CF patients, their clinical phenotype and the effects of CF mutants on the CFTR Cl- channel.  For 
example, Van Goor et al.68 speculated that restoration of 5 – 30% of wild-type CFTR function to 
CF patients bearing the F508del mutation would be of therapeutic benefit.  Using biochemical 
and functional data and the relationship ICFTR = N x i x Po (ICFTR, CFTR-mediated apical 
membrane Cl- current; N, the number of CFTR Cl- channels in the apical membrane; i, the 
amount of current that flows through an open CFTR Cl- channel and Po, a measure of its 
activity), it is possible to predict how much function different therapeutic strategies restore to CF 
mutants in vitro.99  By contrast, it is not possible to quantify CFTR function in vivo using 
currently available research tools (e.g. NPD), while measures of lung function (e.g. FEV1) lack 
sensitivity during the crucial early stages of lung disease.  These considerations argue that 
improvements in disease biomarkers and therapeutic end-points are required to determine how 
much CFTR function is required for therapeutic benefit. 
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 A further obstacle for CF drug development is the use of animal models to demonstrate 
therapeutic proof of principle.  The failure of mouse models of CF to recapitulate the clinical 
features of CF100 limits their utility in preclinical studies of experimental therapeutics.  
Furthermore, the lack of effects of CFTR potentiators on murine CFTR,101,102 argues that these 
agents should not be tested in CF mice.  To overcome these difficulties, Vertex Pharmaceuticals 
employed well-differentiated primary cultures of human airway epithelia grown at an air-liquid 
interface for therapeutic proof of principle studies.84  The success of this approach argues that 
primary cultures of human airway epithelia are the model system of choice for therapeutic proof 
of principle studies.  However, the emergence of animal models that emulate the clinical features 
of CF (e.g. F508del-CFTR pigs),103 argues that testing small-molecule therapies in animal 
models should now be reevaluated. 
 
 Finally, the prospects of designing rationally better CFTR correctors and potentiators 
beckons.  The binding sites of some CFTR correctors, potentiators and dual-acting molecules are 
beginning to be revealed.98  Precise mapping of these sites will require further understanding of 
CFTR structure and how it is perturbed by CF mutations.  Advances in the structural biology of 
CFTR (e.g. Rosenberg et al.104) and modeling CFTR using the structures of related ABC 
transporters and knowledge of CFTR function (e.g. Norimatsu et al.57 and Mornon et al.105) argue 
that rational design might be enhanced.  Such therapeutics will likely have improved efficacy 
and specificity. 
 
1.5 INHIBITION OF CFTR FUNCTION 
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 Secretory diarrhoea, ADPKD and some reproductive disorders are characterised by 
unphysiological CFTR-mediated transepithelial fluid and electrolyte movements.12,13,15  The 
cellular mechanism of CFTR-mediated transepithelial ion transport suggests a number of targets 
for pharmacological intervention to prevent unphysiological fluid and electrolyte movements.  
These targets include the basolateral membrane ion channels and transporters that accumulation 
Cl- within epithelial cells, signaling molecules that regulate CFTR activity and CFTR, itself.  
There are two general mechanisms by which small-molecules inhibit directly the CFTR Cl- 
channel: allosteric inhibition (e.g. CFTRinh-172)106,107 and open-channel blockade (e.g. 
glibenclamide).108  Agents that act as allosteric inhibitors bind to CFTR and interfere with 
channel gating to hinder Cl- entry into the channel pore (Fig. 7).  By contrast, ligands that act as 
open-channel blockers bind within the open channel pore to obstruct transmembrane Cl- flow 
(Fig. 7). 
 
 Using conventional assays of CFTR function, many chemically diverse small-molecule 
CFTR inhibitor have been identified (for review, see Hwang & Sheppard77 and Schultz et al.109).  
However, few of these agents are high-affinity CFTR inhibitors and none demonstrate 
specificity.  Allosteric inhibitors interact with other targets within cells at concentrations similar 
to those that inhibit CFTR, while open-channel blockers of CFTR invariably block other types of 
Cl- channels. 
 
1.5.1 CFTR inhibitors and secretory diarrhoea 
 In search of lead compounds to develop therapeutically-active CFTR inhibitors for 
secretory diarrhoea, Alan Verkman deployed the HTS assay used with great success to identify 
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CFTR potentiators.110  By screening 50,000 compounds, Ma et al.106 identified the thiazolidinone 
CFTRinh-172 (Fig. 8).  CFTRinh-172 has several highly desirable properties as a CFTR inhibitor.  
First, potency: CFTRinh-172 reversibly inhibited CFTR Cl- currents with half-maximal inhibitory 
potency (Ki) of ~300 nM, an increase in potency of almost 500-fold compared with the widely 
used CFTR inhibitor glibenclamide.106  Second, specificity: CFTRinh-172 was without effect on 
several epithelial ion channels and transporters, including Ca2+-activated and volume-regulated 
Cl- channels and the ABC transporter P-glycoprotein.106  Third, efficacy: CFTRinh-172 inhibited 
cholera toxin-induced fluid secretion in the small intestine of mice, highlighting its value as a 
lead compound for drug discovery.106  Although CFTRinh-172 has the drawbacks of limited water 
solubility (~20 μM) and reduced potency in intact cells and tissues (Ki ~5 μM),111 it has become 
a very widely used research tool.  To date, it remains the most selective CFTR inhibitor 
available. 
 
 Early studies to identify the mechanism of action of CFTRinh-172 demonstrated that it 
interfered with channel gating without altering single-channel conductance.112  These data 
suggested that CFTRinh-172 might act as an allosteric inhibitor of CFTR.  However, its 
mechanism of action is distinct from other allosteric inhibitors (e.g. genistein)113,114 that interfere 
with the control of CFTR gating by ATP-driven NBD dimerisation by competing with ATP for 
binding to ATP-binding site 2.  First, Kopeikin et al.107 demonstrated that CFTR inhibition by 
CFTRinh-172 occurs from either the open or closed state and does not involve disassembly of the 
NBD dimer, but instead is reminiscent of the inactivation mechanism of voltage-gated cation 
channels.  Second, Taddei et al.112 found that the CF mutation F508del has increased sensitivity 
to CFTRinh-172 compared to wild-type CFTR, while Caci et al.115 showed that mutation of R347, 
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a non-pore lining residue located at the intracellular end of M6, attenuated markedly the 
inhibitory potency of CFTRinh-172.  Taken together, these data raise the possibility that CFTRinh-
172 might interfere with coupling between the NBD dimer and the channel pore. 
 
 Following the identification of CFTRinh-172, Verkman and colleagues screened 100,000 
small-molecules selected for chemical diversity and drug-like properties.111  Among the four new 
classes of CFTR inhibitors identified by the authors, the glycine hydrazides attracted special 
attention because of their unusual mechanism of action.  Previous work had demonstrated that 
open-channel blockers inhibit CFTR by occluding the deep wide intracellular vestibule of the 
CFTR pore and preventing outwardly directed Cl- flow through the channel.77  By contrast, 
Muanprasat et al.111 revealed that glycine hydrazides, such as GlyH-101 (Fig. 8), are open-
channel blockers that occlude the extracellular vestibule of the CFTR Cl- channel.  When GlyH-
101 binds within the extracellular vestibule, Cl- flow from the extra- to the intracellular side of 
the membrane is more strongly attenuated than that in the opposite direction.  Recently, 
Norimatsu et al.116 used induced-fit virtual ligand docking and site-directed mutagenesis to 
identify the GlyH-101-binding site.  The authors’ data argue that GlyH-101 occludes the CFTR 
pore constriction with its hydrophobic naphthalene tail binding in the vicinity of F342 and its 
negatively charged benzene ring interacting with F337 and T338.  These data provide a 
compelling explanation why GlyH-101 is such an effective open-channel blocker of CFTR. 
 
Like CFTRinh-172,106 GlyH-101 strongly inhibited cholera toxin-induced fluid secretion 
in the small intestine of mice.111  However, in marked contrast to CFTRinh-172, which must be 
administered intraperitoneally,106 GlyH-101 was active when added directly to the lumen of the 
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small intestine.111  These data argue that GlyH-101 and related compounds might be developed 
into a non-absorbable drug therapy for secretory diarrhoea.  Towards this goal, Sonawane et 
al.117 synthesized a series of malonic acid dihydrazides (MalH) linked to polar moieties and 
polyethylene glycol (PEG)-coupled butyric acid hydrazides [Gly-(PEG)n] and demonstrated the 
therapeutic potential of these small-molecules for secretory diarrhoea using a mouse model of 
cholera toxin-induced fluid secretion.  To improve the potency and efficacy of their MalH-based 
CFTR inhibitors, Verkman and colleagues adopted two approaches.  First, chemical conjugation 
with lectins to form MalH-lectins.118  Second, formation of divalent, macromolecular MalH 
conjugates (MalH-PEG-MalH).119  Of note, the small-molecules developed by Verkman and 
colleagues118,119 possess a number of important properties that make them excellent lead 
compounds for secretory diarrhoea therapy development.  These include high water solubility; 
low toxicity; potent inhibition of CFTR and cholera toxin-induced intestinal fluid secretion; 
efficacy when delivered directly into the intestine; minimum absorption by intestinal epithelial 
cells, but stable binding to the glycocalyx covering intestinal epithelial cells to resist drug 
washout. 
 
The data of Sonawane et al.119 suggest that non-absorbable divalent polyethylene glycol-
malonic acid hydrazides are likely to be especially valuable in the development of rational new 
therapies for enterotoxin-induced secretory diarrhoea.  However, the cost of such therapies might 
preclude their widespread use in developing countries, where treatment costs should be around 
US$1 per patient per day.120  Nevertheless, One World Health (San Francisco, California, USA) 
in collaboration with BioFocus (Saffron Walden, Essex, UK) have developed glycine hydrazide 
derivatives where the labile acyl hydrazone is substituted with a stable heterocycle (e.g. 
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iOWH032; Fig. 8).120  Based on the success of preclinical studies, clinical trials of iOWH032 
began in 2011.120 
 
1.5.2 CFTR inhibitors and ADPKD 
 Hanaoka & Guggino40 first explored the therapeutic potential of CFTR inhibitors in 
ADPKD.  The authors demonstrated that diphenylamine-2-carboxylate (DPC)121 and 
glibenclamide,108 two non-specific CFTR inhibitors, diminished ADPKD cyst growth in vitro, 
whereas 4,4’-diisothiocyanatostilbene-2,2’-disulphonic acid (DIDS), which inhibits other types 
of epithelial Cl- channels, but not CFTR, when added to the outside of cells109 was without 
effect.  Building on these data Li et al.122 used Madin Darby canine kidney (MDCK) cells as a 
model system to explore the effects of ion transport inhibitors on renal cyst formation and 
growth.  The data demonstrate that renal cyst growth is retarded by: (i) small-molecules that 
inhibit directly CFTR by allosteric and open-channel blockade mechanisms; (ii) agents that act 
indirectly by inhibiting PKA-dependent phosphorylation of CFTR and (iii) chemicals that 
interfere with the basolateral membrane ion channels and transporters responsible for Cl- 
accumulation within epithelial cells.122  Two important conclusions can be drawn from the data 
of Li et al..122  First, the pharmacology of renal cyst growth resembles that of the CFTR Cl- 
channel.  Second, inhibition of cyst growth by CFTR blockers is correlated with blockade of 
cAMP-stimulated transepithelial Cl- secretion, not cell proliferation. 
 
 As for secretory diarrhoea, the therapeutic potential of CFTR inhibitors in ADPKD has 
been strengthened significantly by the identification of CFTR inhibitors by HTS.  Building on 
the observation that CFTRinh-172 retarded cyst formation and growth,122 Yang et al.123 screened 
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32 CFTR inhibitors related to CFTRinh-172 and GlyH-101 for their ability to block cyst 
formation and growth.  Through these studies, Yang et al.123 identified tetrazolo-CFTRinh-172 
and Ph-GlyH-101, two small-molecules that efficaciously inhibit cyst formation and 
enlargement, without affecting MDCK cell proliferation or inducing apoptosis.  When tested 
using a neonatal kidney organ culture model of cyst formation and growth, both tetrazolo-
CFTRinh-172 and Ph-GlyH-101 reduced markedly the formation of cysts.123  Based on these data, 
Yang et al.123 investigated the effects of tetrazolo-CFTRinh-172 and Ph-GlyH-101 on cyst 
formation and kidney enlargement in vivo using polycystin-1 knockout mice.  Of special note, 
both CFTR inhibitors reduced cyst formation and decreased kidney size in polycystin-1 knockout 
mice, demonstrating convincingly proof of concept for the use of CFTR inhibitors in ADPKD.123 
 
 Despite their effectiveness as inhibitors of renal cyst growth,122,123 thiazolidinones, such 
as CFTRinh-172, have reduced potency in intact cells because their negative charge hinders 
small-molecule accumulation within the cytoplasm.124  In search of new CFTR inhibitors with 
increased potency, Verkman and colleagues screened more than 100,000 small synthetic and 
natural compounds using their HTS assay.  Following electrophysiological evaluation of active 
compounds, Tradtrantip et al.124 identified a new class of CFTR inhibitors, pyrimido-pyrrolo-
quinoxalinedione (PPQ) compounds.  In contrast to other CFTR inhibitors, PPQs are uncharged 
at physiological pH.124  The most potent ligand within this chemical class, PPQ-102 inhibited 
CFTR Cl- currents by a voltage-independent mechanism that increases channel closed-time 
without altering current flow through open channels.124  These data suggest that PPQ-102 is an 
allosteric inhibitor of CFTR.  However, further experiments are required to determine whether its 
mode of action is similar to CFTRinh-172 or genistein. 
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 When tested in polarised epithelia, PPQ-102 inhibited CFTR-mediated transepithelial Cl- 
secretion in FRT epithelia expressing recombinant human CFTR with IC50 ~90 nM and airway 
and intestinal epithelia expressing native CFTR with IC50 < 1 μM.124  To begin to explore the 
therapeutic potential of PPQ-102 in ADPKD, Tradtrantip et al.124 used their neonatal kidney 
organ culture model of cyst formation and growth.  In this assay, PPQ-102 was more effective 
than either tetrazolo-CFTRinh-172 or Ph-GlyH-101 at preventing cyst formation and 
growth.123,124  Because PPQ-102 had poor metabolic stability, Snyder et al.125 synthesized PPQ 
and benzopyrimido-pyrrolo-oxazine-dione (BPO) analogues.  Like PPQ-102, the most potent 
small-molecule identified BPO-27 (Fig. 8) was uncharged at physiological pH.125  However, it 
exhibited >10-fold metabolic stability than PPQ-102 when tested in hepatic microsomes.125  
Strikingly, BPO-27 inhibited CFTR-mediated transepithelial Cl- secretion in FRT epithelia 
expressing recombinant human CFTR with IC50 ~8 nM and prevented cyst formation and growth 
in cultured neonatal kidneys with IC50 ~100 nM, a 5-fold improvement over PPQ-102.124,125  
These data argue persuasively that BPO-27 is an excellent lead compound for testing in animal 
models of ADPKD. 
 
1.5.3 Towards the therapeutic application of CFTR inhibitors 
 The evaluation of the therapeutic potential of CFTR inhibitors has reached an exciting 
stage.  There is understanding of their mechanism of action, efficacious lead compounds have 
been tested in animal models and clinical trials of one CFTR inhibitor have been initiated for 
secretory diarrhoea.  But, what of the future?  First, it will be important to establish the 
specificity of lead compounds by testing these small-molecules on a battery of targets, including 
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ion channels and transporters commonly found in epithelial tissues.  Little information is 
currently available about the specificity of BPO-27,125 CFTRinh-172 appears quite selective for 
CFTR (Ma et al.106 but, see Kelly et al.126), whereas GlyH-101 is less specific, inhibiting the 
Ca2+-activated Cl- channel TMEM16A,127 SLC26 transporters128 and various cation channels in 
cardiac myocytes.129  Second, it is unknown whether CFTR inhibitors, by themselves, will be an 
effective therapy for ADPKD.  The observation that neither tetrazolo-CFTRinh-172 nor Ph-GlyH-
101 affected cell proliferation123 raises the possibility that CFTR inhibitors might need to be 
given in combination with a small-molecule that inhibits cAMP-stimulated cell proliferation, a 
key element in the pathogenesis of ADPKD.40  Third, cyst growth occurs slowly, over decades in 
ADPKD patients.37  There is therefore concern that long-term treatment of ADPKD patients with 
CFTR inhibitors might lead to the development of CF-like symptoms.  The toxicity of CFTR 
inhibitors will therefore need to be evaluated rigorously prior to their use in the clinic.  Finally, 
small-molecule CFTR inhibitors work by inhibiting the activity of individual CFTR Cl- channels.  
However, the magnitude of CFTR-mediated Cl- secretion across the apical membrane of an 
epithelium is determined both by the number of CFTR channels in the apical membrane and the 
activity of individual channels (see above, Section 1.4.4 Towards the therapeutic application of 
CFTR correctors and potentiators).  Based on the effects of the F508del-CFTR mutation on 
renal cyst formation and growth in vivo and in vitro,130-132 an alternative strategy to retard cyst 
formation and growth in ADPKD would be to eliminate the apical membrane expression of 
CFTR.  In support of this idea, pioglitazone, a peroxisome proliferator-activated receptor-γ 
(PPARγ) agonists attenuated sharply CFTR-mediated transepithelial Cl- secretion by decreasing 
CFTR mRNA levels in vitro133 and abrogated cyst growth in vivo.134  It will therefore be 
 
 
33 
 
interesting to evaluate further the therapeutic potential of pioglitazone and related agents using 
polycystin-1 knockout mice. 
 
1.6 CONCULSION 
The success of ivacaftor in clinical trials demonstrates convincingly that small-molecules 
that target directly CFTR have significant therapeutic potential.  In the case of CF, personalized 
medicines might be developed to target precisely the genetic defects harboured by individuals 
afflicted by the disease.  Early intervention with these medicines is expected to improve 
significantly the life expectancy and quality of life of CF patients.  In the case of secretory 
diarrhoea and ADPKD, preclinical studies have demonstrated convincingly the therapeutic 
promise of CFTR inhibitors.  The challenge now is to successfully translate these results into 
benefits for patients in the clinic.  Finally, the success of ivacaftor is a paradigm for the creation 
of therapeutics targeting the root cause of other genetic diseases. 
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FIGURE LEGENDS 
Figure 1: Role of CFTR in transepithelial fluid and electrolyte movements  (A) CFTR-
driven fluid secretion lubricates ducts and tubes.  (B) CFTR-mediated Cl- absorption in sweat 
duct epithelia.  (C) Regulation of ASL by CFTR.  See text for further information. 
 
Figure 2: F508del-CFTR disrupts CFTR channel gating  Representative recordings of wild-
type and F508del-CFTR Cl- channels in excised inside-out membrane patches from cells 
expressing recombinant human CFTR.  ATP (1 mM) and PKA (75 nM) were continuously 
present in the intracellular solution, voltage was -50 mV, there was a large Cl- concentration 
gradient across the membrane patch ([Cl-]int, 147 mM; [Cl-]ext, 10 mM) and temperature was 37 
°C.  Dotted lines indicate where channels are closed and downward deflections of the traces 
correspond to channel openings. 
 
Figure 3: ATP-driven NBD dimerisation opens the CFTR pore  The schematic model shows 
an activated CFTR Cl- channel.  ATP-driven NBD dimerisation opens the CFTR pore.  The 
magnified NBDs show that each ATP-binding site is formed by the Walker A and B motifs 
(labeled A and B, respectively) of one NBD and the LSGGQ motif of the other NBD.  ATP-
binding site 2 contains a canonical LSGGQ motif, whereas ATP-binding site 1 contains a non-
canonical LSGGQ motif (LSHGH).  ATP-binding site 2 also contains a catalytic base (E1371) at 
the distal end of the Walker B motif, but this residue is absent in site 1 (S573).  The location of 
the CF mutations F508del (surface of NBD1 opposite ICL4), G551D (site 2) and G1349D (site 
1) are shown.  Abbreviations: MSD, membrane-spanning domain; NBD, nucleotide-binding 
domain; P, phosphorylation of the RD; Pi, inorganic phosphate; RD, regulatory domain.  In and 
Out denote the intra- and extracellular sides of the membrane, respectively.  See text for further 
information.  Reproduced, with permission, from Chen et al.135 and Hwang & Sheppard136. 
 
Figure 4: Chemical structures of clinically-tested CFTR correctors and potentiators  
Abbreviations: VX-809, 3-{6-{[1-(2,2-difluoro-1,3-benzodioxol-5-
yl)cyclopropanecarbonyl]amino}-3-methylpyridin-2-yl}benzoic acid; ivacaftor, N-(2,4-di-tert-
butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide. 
 
Figure 5: CFTR potentiators enhance channel gating  Representative recordings show the 
effects of dichlorofluorescein (20 μM), phloxine B (1 μM) and UCCF-853 (10 μM) on the single-
channel activity of wild-type CFTR in excised inside-out membrane patches from cells 
expressing recombinant human CFTR.  With the exception that ATP (0.3 mM) was used to 
support channel activity, experimental conditions were the same as those described in Figure 2.  
Dotted lines indicate where channels are closed and downward deflections of the traces 
correspond to channel openings. 
 
Figure 6: Location of some drug-binding sites on CFTR  Simplified model of an open CFTR 
Cl- channel illustrating the general position of some drug-binding sites.  Some small-molecules 
bind at the NBD dimer interface at a location distinct from the two ATP-binding sites (labeled 
1).  Other small-molecules dock with a cavity formed by deletion of F508 at the interface of 
NBD1 and ICL4 (labeled 2).  Yet other small-molecules bind at the interface of the NBDs and 
MSDs involving ICL 1, 2 and 4 (labeled 3).  For further information, see text and Figure 3.  
Modified with permission from Hwang & Sheppard136 and Sheppard137. 
 Figure 7: Blockade of CFTR by open-channel and allosteric inhibitors  Representative 
recordings show the effects of glibenclamide (50 μM) and CFTRinh-172 (2 μM) on the single-
channel activity of wild-type CFTR in excised inside-out membrane patches from cells 
expressing recombinant human CFTR.  With the exception that ATP (0.3 mM) was used to 
support channel activity, experimental conditions were the same as those described in Figure 2.  
Dotted lines indicate where channels are closed and downward deflections of the traces 
correspond to channel openings. 
 
Figure 8: Chemical structures of some CFTR inhibitors  Abbreviations: CFTRinh-172, 3-[(3-
trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone; GlyH-101, 
N-(2-naphthalenyl)-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene]glycine hydrazide; 
iOWH032, 3-(3,5-dibromo-4-hydroxy-phenyl)-N-[(4-phenoxyphenyl)methyl]-1,2,4-oxadiazole-
5-carboxamide; BPO-27, 6-(5-bromofuran-2-yl)-7,9-dimethyl-8,10-dioxo-11-phenyl-7,8,9,10-
tetrahydro-6H-benzo[b]pyrimido[4’,5’:3,4]pyrrolo[1,2-d][1,4]oxazine-2-carboxylic acid. 
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ABSTRACT 
The cystic fibrosis transmembrane conductance regulator (CFTR) plays a pivotal role in 
fluid and electrolyte movements across ducts and tubes lined by epithelia.  Loss of CFTR 
function causes the common life-limiting genetic disease cystic fibrosis (CF) and a spectrum of 
disorders termed CFTR-related diseases, while unphysiological CFTR activity characterises 
secretory diarrhoea and autosomal dominant polycystic kidney disease (ADPKD).  The 
prevalence of these disorders argues persuasively that small-molecule CFTR modulators have 
significant therapeutic potential.  Here, we discuss how knowledge and understanding of the 
CFTR Cl- channel, its physiological role and malfunction in disease led to the development of 
the CFTR potentiator ivacaftor, the first small-molecule targeting CFTR approved as a treatment 
for CF.  We consider the prospects for developing other therapeutics targeting directly CFTR 
including CFTR correctors to rescue the apical membrane expression of CF mutants, CFTR 
corrector-potentiators, dual-acting small-molecules to correct the processing and gating defects 
of F508del-CFTR, the commonest CF mutant and CFTR inhibitors to prevent fluid and 
electrolyte loss in secretory diarrhoea and cyst swelling in ADPKD.  The success of ivacaftor 
provides impetus to other CFTR drug development programmes and a paradigm for the creation 
of therapeutics targeting the root cause of other genetic disorders. 
 
Keywords: ATP-binding cassette transporter / epithelial ion transport / cystic fibrosis / CFTR 
/ chloride ion channel / channel gating / F508del / CFTR corrector / CFTR potentiator / CFTR 
inhibitor 
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